Larkspur Health (NASDAQ:LSPR) announced this afternoon that it has secured commitments of $10 million for its proposed merger with specialty biopharmaceutical company ZyVersa.
Of that $10 million, $8.5 million will be a PIPE investment in the form of contingent financing that will provide for the purchase of Convertible Preferred Stock of LSPR. Larkspur Health had originally planned to supplement the deal with a $7 million PIPE, which was also contingent upon ZyVersa obtaining additional interim financing, but the SPAC was able to bring in $1.5 million more than expected.
The remaining amount of today’s announced capital is part of a bridge, an interim finance round of approximately $1.5 million. The commitment is from an offering of Series A Convertible Preferred Stock of ZyVersa which will convert into ZyVersa common stock in connection with the transaction.
Capital raised in the bridge will be used to support the advancement of research and development programs and ongoing ZyVersa operations and, along with funds from the PIPE Investment, will be used by the combined company following the business combination for similar purposes.
The PIPE Investment is anticipated to close simultaneously with the closing of the transaction, which is still expected to take place in the fourth quarter of 2022. Upon closing of the deal, Larkspur is expected to be renamed ZyVersa Therapeutics, Inc. and will continue to operate under the ZyVersa management team, led by Stephen C. Glover, Co-Founder, CEO, and Chairman. The combined company’s common stock is expected to be listed on NASDAQ under ticker symbol “ZVSA.”
The SPAC announced its $108.9 million deal with ZyVersa just a few months ago on July 21, 2022. Weston, Florida-based ZyVersa is developing clinical and preclinical treatments for a variety of inflammatory diseases affecting the kidneys and nervous system.
Below is a daily summary of links to the latest SPAC news and rumors gathered across the web. Latest SPAC News: Circle spokesperson denies blaming SEC for failed deal, BuzzFeed CEO says AI-powered content will be part of core business, and FaZe Clan faces possible delisting Circle Spokesperson Denies Blaming SEC for Failed $9 Billion Deal...
Health Sciences 2 (NASDAQ:HSAQ) announced that it closed its combination with Orchestra BioMed on January 26. HSAQ ahead of its vote pre-announced redemption figures of 1,597,888 shares equating to 67.7% redemptions, however, that’s still subject to change. However, today it was noted that Orchestra BioMed is to receive $70 million in gross proceeds including $20...
Carbon capture technology has long been talked about, and it is finally in operation with LanzaTech among the pioneers. Its plants are turning potential emissions into clothing, household goods and sustainable fuels. SPAC cash is now also an accelerant in this new process as the company announced a $1.7 billion combination with AMCI II last March. This week, we caught up with...
In this series we’ll be examining successful SPAC deals from the past both in the terms and circumstances of their de-SPAC processes and how they have weathered the storms that have followed after their public listings with research from SPACInsider contributor Anthony Sozzi. Thirty months does not sound like that long, but it’s been a...
Seaport Calibre Materials Acquisition Corp. (Nasdaq: SCMA) announced this afternoon that it is pushing today’s special meeting back until January 31. The SPAC is currently facing a completion deadline of February 1, but is looking to extend its timeline by an additional six months to August 1. Stockholders may elect to redeem their shares for a pro rata...